HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $27 price target.
March 06, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma with a $27 price target.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst could positively influence investor sentiment towards MRNS, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100